Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
Conditions: Breast Cancer Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer
Conditions: HR+HER2- Breast Cancer Interventions: Drug: BL-B01D1; Drug: Eribulin; Drug: Vinorelbine; Drug: Gemcitabine; Drug: Capecitabine Sponsors: Sichuan Baili Pharmaceutical Co., Ltd.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity
Conditions: Metastatic Breast Cancer; Estrogen-receptor-positive Breast Cancer; Adiposity Interventions: Behavioral: Physical Activity Sponsors: Aarhus University Hospital; Danish Cancer Society Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
Abemaciclib, Palbociclib or Dalpiciclib Combined With Endocrine Therapy as First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
Conditions: Breast Cancer Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
Positive ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-negative Primary Tumor
Conditions: Breast Cancer Sponsors: Fudan University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
Effectiveness of WeChat-assisted preoperative education to reduce perioperative anxiety in breast cancer patients: a prospective randomized controlled study protocol
This study aims to evaluate the use of WeChat public platform as a tool for preoperative education in patients undergoing breast surgery.MethodsThis is a prospective, randomized, and controlled trial will involve 392 adult women scheduled for breast cancer resection. Participants will be randomly assigned to either the WeChat education group or the regular group. In addition to regular preoperative visits, the WeChat education group will also watch science videos through the WeChat public platform. The regular group will only receive education from ward nurses during preoperative visits. The primary outcome measure will be...
Source: Trials - April 3, 2024 Category: Research Source Type: clinical trials
A Retrospective Real-world Study of Abemaciclib Tablets Based on HIS System in HR+ Breast Cancer Patients
Conditions: Breast Cancer; Neoplasms; Breast Diseases Interventions: Drug: Abemaciclib and Letrozole/Anastrozole; Drug: Letrozole or Anastrozole; Drug: Abemaciclib and Fulvestrant; Drug: Fulvestrant Sponsors: The Affiliated Hospital of Qingdao University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
Conditions: Breast Cancer; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma Interventions: Drug: AB-201; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: GC Cell Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
A Qualitative Study on Treatment Adherence in Patients With Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer Sponsors: European Institute of Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib
Conditions: Breast Cancer Interventions: Drug: 3-year abemaciclib without chemo; Drug: treatment of physician ' s choice Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
Conditions: Metastatic Breast Cancer Interventions: Drug: Tiragolumab; Drug: Atezolizumab; Drug: Ipilimumab Sponsors: The Netherlands Cancer Institute; Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
Conditions: Early Breast Cancer Interventions: Drug: Dalpiciclib; Drug: Endocrine therapy Sponsors: The First Affiliated Hospital with Nanjing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity
Conditions: Breast Cancer Interventions: Drug: Dapagliflozin 10mg Tab Sponsors: Fondazione IRCCS Policlinico San Matteo di Pavia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity
Conditions: Cardiotoxicity; Breast Cancer; Treatment Side Effects Interventions: Diagnostic Test: Plasma NT-proBNP Sponsors: Vastra Gotaland Region Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
Italian Validation of a Tool for Assessing Sexual Function After Breast Cancer, FSFI-BC
Conditions: Breast Cancer Sponsors: European Institute of Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
